Surgery Doctors in Auburndale, MA Accepting Medicare

1 Surgery doctors found. Showing 1 - 1

Charles R Bridges, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 106 Pine St, Auburndale, MA 02466 Phone: 610-247-2986    Fax: 704-372-1249

News Archive

Sticking to lifestyle changes will reduce high blood pressure risk

It has been suggested for sometime by a range of research studies that lifestyle changes, such as exercising to lose weight and following a healthy diet, are possibly as important as drugs for treating chronic diseases like diabetes, high cholesterol, and hypertension.

Knee replacement pain predicted by comorbidity

Research may help physicians give patients undergoing total knee arthroplasty a realistic expectation of surgery outcome based on their overall physical and mental health, US researchers believe.

New CWRU study identifies three glycosyltransferases as major mutational targets in colorectal cancer

Little is known about the molecular basis of aberrant protein glycosylation, a complex enzymatic process that is a hallmark of many human cancers including colorectal cancers (CRC), and how it may contribute to tumor progression. In a new study published in Scientific Reports, an online journal of the Nature Publishing Group, scientists at Case Western Reserve University School of Medicine have successfully characterized the mutational landscapes of glycosylation-associated genes in colon cancer, identifying three glycosyltransferases as significant mutational targets in CRC.

New approach to alter intestinal microbiota and protect against inflammatory diseases

Targeted immunization against bacterial flagellin, a protein that forms the appendage that enables bacterial mobility, can beneficially alter the intestinal microbiota, decreasing the bacteria's ability to cause inflammation and thus protecting against an array of chronic inflammatory diseases, according to a new study by the Institute for Biomedical Sciences and the Neuroscience Institute at Georgia State University.

FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL

The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orphan Products Development was granted on August 6th, 2010.

Read more Medical News

› Verified 1 days ago